This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX vs. NGNE, ELDN, IVA, FULC, ANNX, YMAB, RZLT, GOSS, ESPR, and HURAShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Neurogene (NGNE), Eledon Pharmaceuticals (ELDN), Inventiva (IVA), Fulcrum Therapeutics (FULC), Annexon (ANNX), Y-mAbs Therapeutics (YMAB), Rezolute (RZLT), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical preparations" industry. Elicio Therapeutics vs. Neurogene Eledon Pharmaceuticals Inventiva Fulcrum Therapeutics Annexon Y-mAbs Therapeutics Rezolute Gossamer Bio Esperion Therapeutics TuHURA Biosciences Neurogene (NASDAQ:NGNE) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Which has better valuation & earnings, NGNE or ELTX? Elicio Therapeutics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$925K248.73-$36.32M-$4.27-3.61Elicio Therapeutics$2.30M24.07-$35.19M-$6.95-0.74 Which has more volatility & risk, NGNE or ELTX? Neurogene has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Is NGNE or ELTX more profitable? Neurogene's return on equity of -32.81% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -32.81% -27.96% Elicio Therapeutics N/A -555.45%-177.34% Do analysts prefer NGNE or ELTX? Neurogene currently has a consensus price target of $47.20, indicating a potential upside of 206.29%. Elicio Therapeutics has a consensus price target of $10.00, indicating a potential upside of 94.93%. Given Neurogene's stronger consensus rating and higher possible upside, equities analysts plainly believe Neurogene is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Elicio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer NGNE or ELTX? In the previous week, Neurogene had 4 more articles in the media than Elicio Therapeutics. MarketBeat recorded 5 mentions for Neurogene and 1 mentions for Elicio Therapeutics. Neurogene's average media sentiment score of 1.38 beat Elicio Therapeutics' score of 0.00 indicating that Neurogene is being referred to more favorably in the media. Company Overall Sentiment Neurogene Positive Elicio Therapeutics Neutral Do insiders & institutionals have more ownership in NGNE or ELTX? 52.4% of Neurogene shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 9.9% of Neurogene shares are owned by company insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in NGNE or ELTX? Neurogene received 22 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. Likewise, 96.67% of users gave Neurogene an outperform vote while only 87.50% of users gave Elicio Therapeutics an outperform vote. CompanyUnderperformOutperformNeurogeneOutperform Votes2996.67% Underperform Votes13.33%Elicio TherapeuticsOutperform Votes787.50% Underperform Votes112.50% SummaryNeurogene beats Elicio Therapeutics on 14 of the 18 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.35M$6.71B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.29%P/E Ratio-0.747.2322.3918.43Price / Sales24.07239.71391.41101.46Price / CashN/A65.8538.1834.62Price / Book3.806.306.684.19Net Income-$35.19M$143.17M$3.22B$248.05M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics2.0541 of 5 stars$5.13+1.2%$10.00+94.9%-44.3%$55.35M$2.30M-0.74N/AGap UpNGNENeurogene2.1334 of 5 stars$13.83+15.1%$47.20+241.3%-48.4%$206.48M$925,000.00-3.2490Positive NewsELDNEledon Pharmaceuticals2.2003 of 5 stars$3.38+13.4%$12.50+269.8%+60.4%$202.40MN/A-1.6810Short Interest ↑Positive NewsIVAInventiva1.8904 of 5 stars$3.82+7.2%$10.40+172.6%+23.1%$200.20M$9.20M0.00100News CoverageGap UpFULCFulcrum Therapeutics1.9028 of 5 stars$3.65+5.5%$8.63+136.3%-50.5%$197.02M$80M-11.77100Positive NewsANNXAnnexon2.093 of 5 stars$1.76+4.8%$18.67+960.6%-59.0%$193.09MN/A-1.6860Positive NewsGap DownHigh Trading VolumeYMABY-mAbs Therapeutics3.6315 of 5 stars$4.26-11.6%$17.40+308.5%-72.4%$192.63M$87.69M-7.89150Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownRZLTRezolute2.5211 of 5 stars$3.11-1.0%$26.43+749.8%+48.1%$188.26MN/A-2.5540Short Interest ↑News CoveragePositive NewsGOSSGossamer Bio3.7098 of 5 stars$0.83+1.8%$7.50+806.5%+43.0%$188.00M$114.70M-2.59180Positive NewsESPREsperion Therapeutics3.353 of 5 stars$0.93+9.1%$6.42+590.2%-53.8%$183.94M$332.31M-1.45200Analyst ForecastNews CoverageHURATuHURA BiosciencesN/A$4.08-2.9%$12.67+210.5%N/A$178.21MN/A0.00N/APositive News Related Companies and Tools Related Companies NGNE Competitors ELDN Competitors IVA Competitors FULC Competitors ANNX Competitors YMAB Competitors RZLT Competitors GOSS Competitors ESPR Competitors HURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELTX Stock Free ELTX Stock Alerts